The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recently updated chronic obstructive pulmonary disease (COPD) treatment guidelines, limiting indications for inhaled corticosteroids (ICS) to more accurately reflect evidence regarding their appropriate use (1) . The primary effect of ICS therapy in patients with COPD is to reduce the risk of exacerbations (2) . Systematic reviews have demonstrated that ICS also increase the risk of harm, including pneumonia, poor diabetes control, cataracts, and bone fractures (2) . Among patients at low risk for COPD exacerbations, ICS have no demonstrated efficacy but retain the risk of harm.
GOLD guidelines recommend reserving ICS for patients who are at high risk for future exacerbations. Whereas the 2015 GOLD guidelines define high risk based on frequent exacerbations in the prior year (two or more outpatient exacerbations or one or more inpatient exacerbations) and/or severity of airflow obstruction (AFO) (FEV 1 < 50% predicted), the 2017 guidelines define high risk based only on frequent exacerbations, acknowledging evidence that patients with isolated severe AFO are unlikely to benefit from ICS therapy (1, 3) . Prior analyses of updated GOLD guidelines suggested that the 2017 revision shifted many patients from highto low-risk categories, although the impact of these changes on ICS-prescribing patterns is unknown (4, 5) . Our objective was to examine how changes in the GOLD guidelines could impact ICS prescriptions for veterans with COPD.
Methods
We conducted an observational study of veterans with COPD who had pulmonary function tests (PFTs) recorded in the Veteran Affairs (VA) Corporate Data Warehouse during the period of 3/15/2012 to 9/15/2016. We included patients with a diagnosis of COPD and AFO on PFTs based on postbronchodilator FEV 1 /FVC , 0.7. We excluded patients with a diagnosis of asthma. We identified inpatient and outpatient COPD exacerbations using VA administrative data. Although we were not able to ascertain exacerbations that occurred outside of the VA, we have previously demonstrated that non-VA healthcare use among veterans with COPD is low (6, 7).
Using the date of the most recent PFTs as the index date, we identified 1) COPD exacerbations during 12 months before index, and 2) any ICS prescription that occurred during 6 months after index. We then compared the proportion of patients who met indications for ICS therapy based on GOLD recommendations from 2015 (severe AFO and/or frequent exacerbations) versus 2017 (only those with frequent exacerbations). We also evaluated the concordance of existing ICS prescriptions with 2015 versus 2017 guidelines, and compared patient characteristics (including International Classification of Diseases [ICD] comorbidity codes) for all patients with ICS prescriptions (including ICS before PFTs and new starts). In a secondary analysis, we examined the impact of guideline changes only on patients who were started on new ICS after PFTs. We used chi-squared and t tests to compare patient characteristics (including ICD comorbidity codes) for patients who had guideline-concordant versus -discordant existing ICS prescriptions.
Results
We identified 42,478 patients who had a diagnosis of COPD and AFO detected on PFTs. Among 17,509 patients with existing ICS prescriptions (including ICS before PFTs and new starts), 2,484 (14.2%) received treatment that was discordant with the 2015 guidelines, whereas applying the 2017 guidelines increased discordant treatment to 14,682 (83.9%). Among 4,635 patients who were started on ICS after PFTs, guideline discordance occurred in 817 (17.6%) according to 2015 guidelines and in 4,387 (94.6%) according to 2017 guidelines. Patients with existing ICS prescriptions that were not concordant with 2017 guidelines were less likely to have comorbidities, such as heart failure (14.3% vs. 23.4%, P , 0.01), arrhythmias (21.6% vs. 30.3%, P , 0.01), and renal disease (10.0% vs. 12.1%, P , 0.01) ( Table 1) . Guideline-discordant ICS treatment was also associated with fewer other COPD medications, including short-acting b-agonists (66.6% vs. 88.6%, P , 0.01), long-acting b-agonists (63.5% vs. 87.2%, P , 0.01), and long-acting muscarinic antagonists (34.9% vs. 62.1%, P , 0.01).
Discussion
Our results suggest that implementation of updated GOLD guidelines could substantially reduce ICS use among patients with COPD, averting adverse effects among patients who may not benefit from ICS therapy and focusing treatment on patients who do. The evolution of the high-risk classification in the GOLD guidelines highlights the effect that modest changes in disease definitions can have on patient care. The VA provides care for nearly 1 million veterans with COPD, and approximately 40% of these patients are maintained on ICS therapy (8).
Overuse of ICS is common. Even when the more liberal 2015 guidelines were used, 14% of existing ICS prescriptions were not concordant with the guidelines, and these proportions increased dramatically when the more stringent 2017 guidelines were applied. Overuse of ICS also tends to occur in patients who have poor guideline concordance as evident by underuse of other COPD medications. Among patients with ICS prescriptions that are concordant with the 2017 guidelines (defined by frequency of COPD exacerbations), comorbidities such as heart failure could mimic COPD exacerbations. Although ICD codes are not perfect measures of disease diagnosis, the indication that these comorbidities may be more common among patients with guideline-concordant ICS prescriptions suggests that additional efforts may be needed to discriminate COPD exacerbations from other causes of respiratory distress (9).
Recently published analyses of prospective studies showed that the updated GOLD guidelines led to large changes in the COPD classification of risk for future exacerbations, with many patients shifting from high-risk categories (GOLD groups C and D) to low-risk categories (GOLD groups A and B) (4, 5) . Using a national observational data set, our study shows a similar impact on classification of exacerbation risk, and the vast majority of ICS use in our study would no longer be concordant with updated guidelines.
National initiatives, such as those led by Choosing Wisely, focus quality-improvement initiatives on deimplementing nonbeneficial therapies to optimize care (10). Changes to the GOLD guidelines align recommended COPD therapies with available evidence, narrowing the indication for ICS and averting their adverse effects. Ensuring guideline concordance for ICS therapy could affect many patients with COPD, improving the value and safety of COPD care. n Author disclosures are available with the text of this letter at www.atsjournals.org. To the Editor:
Treatment outcomes of conventional multidrug-resistant tuberculosis (MDR-TB) treatments are overall unsatisfactory, particularly for fluoroquinolone-resistant MDR-TB (1). In addition, long-term follow-up studies have shown that patients who have experienced previous treatment failure contribute importantly to ongoing transmission in the community (2) . The introduction of two new drugs, bedaquiline and delamanid, has been reported to improve treatment outcomes for MDR/extensively drugresistant (XDR)-TB (3, 4) . In addition, there is growing evidence that repurposed drugs such as linezolid, clofazimine, and carbapenems with amoxicillin/clavulanate also have a role to play in MDR/XDR-TB treatment (5, 6). However, few reports have assessed new regimens rather than the addition of a single new or repurposed drug to a regimen (3, 4, 6) . In Armenia, Médecins Sans Frontières (MSF) has supported the National Tuberculosis Program for the treatment of MDR-TB patients since 2005. In 2013, bedaquiline was introduced into clinical practice through a compassionate use (CU) mechanism. At the same time, the repurposed drugs linezolid and imipenem/cilastatin became available for the first time. Clofazimine was already available. The objective of this study was to assess the clinical impact of regimens containing bedaquiline, linezolid, and/or imipenem/cilastatin.
